SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS thesis, with traders debating how much the new entrant could threaten its sales. Some see Precigens commercial head start and full approval as advantages, while others focus on the rivals potential to reduce surgeries and challenge PAPZIMEOS.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A third-quarter earnings beat and raised full-year revenue outlook, driven by demand for Mounjaro and Zepbound, have fueled LLYs move to record highs. Traders largely welcome the GLP-1 growth and analyst upgrades, while some point to reduced profit guidance tied to acquisition charges, rich valuation, and weaker-than-expected Foundayo sales as risks.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a broad tech and semiconductor selloff as traders reassess whether heavy AI infrastructure spending can generate sufficient returns, alongside weak tech earnings and concerns about financing. The community is split between calling the decline a capitulation-driven buying opportunity and warning that the AI trade could face further downside.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is under pressure amid a broad technology-sector correction, with traders pointing to concerns about AI spending, debt and uncertain returns; some blame Blackstones warning about Anthropics credit outlook for worsening the sell-off. The debate is between bearish calls for more downside and investors treating the pullback as a buying opportunity.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention as the highly anticipated GTA VI launch approaches, with traders debating whether expected sales and future online revenue can lift shares. Bulls are buying the pullback on blockbuster potential, while skeptics cite launch expectations already priced in, possible sell-the-news pressure, and leak or piracy risks.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstones exposure to AI infrastructure financing is drawing scrutiny after traders circulated claims that it expects Anthropic to receive a speculative-grade credit rating, against the backdrop of a large chip-financing deal. Some view the credit-risk concerns as warranted, while others accuse Blackstone of issuing a poorly timed hit piece; call-heavy options flow is also being watched.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs run to a 52-week high has traders focused on an expected Q3 earnings report and continued BRIUMVI sales growth. Some attribute the move to earnings expectations and short covering, while others speculate about a buyout; no acquisition has been confirmed, and the earnings date remains uncertain.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas selection for the S&P 500 is drawing attention, with traders noting potential index-fund buying but debating whether the news could lead to a sell-the-news pullback. The discussion also reflects caution about the stocks recent run and weakness in cybersecurity shares.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares quarterly recalculations could reduce DefenCath reimbursement in 2027 has fueled concern about pricing and sales, alongside a sharp share-price decline. Traders dispute how much weight to give DaVitas preliminary outlook, arguing that CMSs finalized rate points to a more stable picture, while others remain concerned about reimbursement and adoption.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention over its monthly distribution as Nasdaq weakness weighs on the fund. Income-focused traders are discussing the payout and buying the dip, while others emphasize that its covered-call strategy can cushion declines but does not prevent losses and limits some upside in rallies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sj?gren's trial was halted for futility; others also slid.read more...

CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs

Equity

Caribou said it would stop work on both of its clinical-stage CAR-T programs and consider strategic options including a merger, acquisition, or sale of assets.


Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why

Caribou Biosciences shares fall 35% after hours as the company weighs strategic alternatives and cuts two drug programs.read more...

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now

IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 0.00% and -47.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging  Caribou Biosciences (CRBU) This Year?

Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.

Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows

Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows...

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Caribou Biosciences Inc

Bearish Sentiment

<ul class="summary-bullets"><li>RBC Capital downgrades to ‘Sector Perform’ from ‘Outperform’ and cuts price target to $1 from $10.</li><li>Caribou will also reduce its workforce.</li><li>The company had $113.8 million in cash, cash equivalents and marketable securities as of June 30.</li></ul>Shares of Caribou Biosciences (CRBU) crashed more than 35% in pre-market trading on Wednesday, as Wall Street sharply cut its price target after the biotech firm said it would scale back its cancer-drug development efforts.If levels hold after the market opens,&nbsp;<a href="https://stocktwits.com/symbol/CRBU">CRBU shares</a> would hit a new 52-week low and clock their biggest single-day slide ever.<h2 class="st-heading-2">CRBU Set To Reduce Workforce By Q4</h2>After market hours on Tuesday, Caribou said it would stop work on both of its clinical-stage CAR-T programs while considering strategic options including a merger, acquisition, or sale of assets.Caribou will also substantially reduce its workforce, which it expects to mostly complete during the fourth quarter (Q4) of 2026.The firm will discontinue the development of Vispa-Cel and CB-011. Vispa-Cel was being developed for relapsed or refractory B-cell non-Hodgkin lymphoma. It targets a protein found on certain B-cell cancers. Caribou and the FDA had agreed on the design of a potential Phase 3 study.CB-011 targets a protein commonly found on multiple myeloma cells, and was being studied in a Phase 1 trial. Both programs had received U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations, intended to speed development of treatments for serious diseases.“Unfortunately, despite the progress we've made, the current financing environment for allogeneic CAR-T cell therapies has made it increasingly challenging to secure the capital necessary to responsibly advance these programs. As a result, we’ve made the difficult decision to evaluate strategic alternatives and plan to discontinue further development of our allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, president and CEO of Caribou.<h2 class="st-heading-2">Wall Street Slashes Price Target To $1</h2>RBC Capital downgraded Caribou Biosciences to ‘Sector Perform’ from ‘Outperform’ and reduced the price target to $1 from $10, according to The Fly. Meanwhile, Leerink downgraded Caribou to ‘Market Perform’ from ‘Outperform’ and cut the price target to $1 from $4, citing reduced visibility into Caribou’s outlook as an ongoing entity after the discontinuation of the programs.The company had $113.8 million in cash, cash equivalents and marketable securities as of June 30, down from $142.8 million at the end of 2025.<h2 class="st-heading-2">Retail Expects CRBU To Slump Further</h2>Despite the pre-market slump, retail sentiment for CRBU on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid a 2,033% surge in message volumes.One user expects the stock to keep declining until the company finds a buyer for its two pipeline assets.<stembedurl>https://stocktwits.com/moontomorrow/message/665921838</stembedurl>The stock is down more than 53% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative Image (Photo credit: Getty Images)

Caribou said it would stop work on both of its clinical-stage CAR-T programs and consider strategic options including a merger, acquisition, or sale of assets.

Why Is CRBU Stock Crashing Today?

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.4232
Prev Close	$0.445
Open	$0.445
Dividend Yield	0.00%
50-Day Moving Average	$1.07
Beta	1.92
Avg. Volume	1.18M
PE Ratio	-0.39

52-Week High	$3.54
52-Week Low	$0.4135
Market Capitalization	$47.71M
EPS (Annual)	-$1.59
Price to Book	0.46
Revenue Per Employee	$115,041.24

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRBU Fundamentals